Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

Vor Biopharma (NYSE:VOR - Get Free Report) was upgraded by research analysts at HC Wainwright from a "neutral" rating to a "buy" rating in a report issued on Monday, MarketBeat Ratings reports. The firm presently has a $3.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 183.02% from the stock's previous close.

Other research analysts have also recently issued reports about the company. Jones Trading cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Oppenheimer reissued an "outperform" rating and set a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Baird R W downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday. Finally, Stifel Nicolaus lowered their target price on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.63.

Vor Biopharma Trading Up 19.1%

Shares of VOR opened at $1.06 on Monday. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $1.80. The firm has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $0.83. The stock has a market capitalization of $132.46 million, a price-to-earnings ratio of -0.64 and a beta of -0.51.

Institutional Trading of Vor Biopharma

Several large investors have recently made changes to their positions in VOR. Virtu Financial LLC acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at $60,000. XTX Topco Ltd acquired a new stake in Vor Biopharma in the fourth quarter valued at about $80,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Vor Biopharma in the fourth quarter valued at about $33,000. Lynx1 Capital Management LP acquired a new position in Vor Biopharma during the fourth quarter worth about $707,000. Finally, Northern Trust Corp lifted its holdings in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after acquiring an additional 44,252 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.